NCT04991571View on ClinicalTrials.gov

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 29, 2021

Primary Completion Date

October 22, 2021

Study Completion Date

October 22, 2021

Conditions
Chronic Kidney Disease
Interventions
DRUG

Zibotentan (Treatment A)

Zibotentan capsule will be administered orally as multiple doses in Part 1 and as single dose in Part 2.

DRUG

Dapagliflozin (Treatment A)

Dapagliflozin tablet will be administered orally as single dose in Part 2.

DRUG

Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)

Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.

DRUG

Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)

Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.

Trial Locations (1)

21225

Research Site, Brooklyn

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY